MRI contrast developer Epix Pharmaceuticals of Lexington, MA, said it has been advised by the Nasdaq listing and hearing review council that it has regained compliance with listing requirements and is eligible to continue to trade on the exchange.
The firm had delayed filing its fiscal 2006 Form 10-K in order to review past stock option practices. The company said its 10-K filed this week was adjusted to reflect the restatement of its financial results. The adjustments did not affect previously reported revenue, cash, cash equivalents, or marketable securities balances in any of the restated periods and relate exclusively to stock option practices, according to Epix.
By AuntMinnie.com staff writers
April 13, 2007
Related Reading
Epix Pharma says decision on contrast agent may take longer, April 3, 2007
Epix files formal appeal for Vasovist, February 28, 2007
Epix to restate past financial reports, February 26, 2007
Epix files U.S. Vasovist appeal, December 15, 2006
Epix releases clinical trial results for blood-clot agent, November 30, 2006
Copyright © 2007 AuntMinnie.com
